How therapeutic advances have transformed the medical landscape: a primer for clinicians.
clinical practice
clinical research
drug development
funding
pharmaceuticals
reimbursement
Journal
Internal medicine journal
ISSN: 1445-5994
Titre abrégé: Intern Med J
Pays: Australia
ID NLM: 101092952
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
20
02
2023
accepted:
26
05
2023
medline:
31
5
2023
pubmed:
31
5
2023
entrez:
31
5
2023
Statut:
ppublish
Résumé
Novel medicines are entering the market rapidly and are increasingly being used alone or in combination to treat illnesses of every sort. While transforming the lives of many patients, these new therapies have also forced us to reconsider the way we evaluate, use and fund medicines. This article offers a primer to help practitioners understand how the therapeutic landscape is changing and how this might impact the evidence generation, access to interventions, patient experience and quality of care.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1306-1310Informations de copyright
© 2023 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians.
Références
Larson RC, Maus MV. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer 2021; 21: 145-61.
Tanne JH. FDA approves $3.5m gene therapy for adults with haemophilia B. BMJ 2022; 379: o2858.
Dunn B, Stein P, Cavazzoni P. Approval of aducanumab for Alzheimer disease-the FDA's perspective. JAMA Intern Med 2021; 181: 1276-8.
Arlett P, Kjaer J, Broich K, Cooke E. Real-world evidence in EU medicines regulation: enabling use and establishing value. Clin Pharmacol Ther 2022; 111: 21-3.
Pace J, Ghinea N, Kerridge I, Lipworth W. Demands for access to new therapies: are there alternatives to accelerated access? BMJ 2017; 359: j4494.
Godman B, Hill A, Simoens S, Selke G, Selke Krulichová I, Zampirolli Dias C et al. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Rev Pharmacoecon Outcomes Res 2021; 21: 527-40.
Jørgensen J, Kefalas P. The use of innovative payment mechanisms for gene therapies in Europe and the USA. Regen Med 2021; 16: 405-22.
Thall PF. Adaptive enrichment designs in clinical trials. Annu Rev Stat Appl 2021; 8: 393-411.
Ballarini NM, Burnett T, Jaki T, Jennison C, König F, Posch M. Optimizing subgroup selection in two-stage adaptive enrichment and umbrella designs. Stat Med 2021; 40: 2939-56.
Lengliné E, Peron J, Vanier A, Gueyffier F, Kouzan S, Dufour P et al. Basket clinical trial design for targeted therapies for cancer: a French National Authority for Health statement for health technology assessment. Lancet Oncol 2021; 22: e430-4.
Superchi C, Bouvier FB, Gerardi C et al. Study designs for clinical trials applied to personalised medicine: a scoping review. BMJ Open 2022; 12: e052926.
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Anderson J et al. Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial. BJU Int 2009; 103: 464-9.
Kahan BC, Jairath V. Outcome pre-specification requires sufficient detail to guard against outcome switching in clinical trials: a case study. Trials 2018; 19: 265.
National Cancer Policy Forum. Scientific Challenges in Developing Investigational Combination Therapies. USA: National Academies Press 2011. Available from URL: https://www.ncbi.nlm.nih.gov/books/NBK189894/
Caffo O. Treatment sequencing in oncology: balancing clinical trial and real-world evidence. Future Oncol 2019; 15: 2887-9.
Braithwaite T, Calvert M, Gray A, Pesudovs K, Denniston A. The use of patient-reported outcome research in modern ophthalmology: impact on clinical trials and routine clinical practice. Patient Relat Outcome Meas 2019; 10: 9-24.
Kool M, van der Sijp JRM, Kroep JR, Liefers GJ, Jannink I, Guicherit OR et al. Importance of patient reported outcome measures versus clinical outcomes for breast cancer patients evaluation on quality of care. Breast 2016; 27: 62-8.
Research C for DE and. Table of Surrogate Endpoints That Were the Basis of Drug Approval or Licensure. FDA. Published Online First: 28 February 2022.Available from URL: https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure
Stoller JK. The challenge of rare diseases. Chest 2018; 153: 1309-14.
Ratner M, Gura T. Off-label or off-limits? Nat Biotechnol 2008; 26: 867-75.
Mills M, Kanavos P. How do HTA agencies perceive conditional approval of medicines? Evidence from England, Scotland, France and Canada. Health Policy 2022; 126: 1130-43.
Hoekman J, Klamer TT, Mantel-Teeuwisse AK, Leufkens HGM, de Bruin ML. Characteristics and follow-up of postmarketing studies of conditionally authorized medicines in the EU. Br J Clin Pharmacol 2016; 82: 213-26.
Lidz CW, Appelbaum PS, Grisso T, Renaud M. Therapeutic misconception and the appreciation of risks in clinical trials. Soc Sci Med 2004; 58: 1689-97.
McCormick JB. How should a research ethicist combat false beliefs and therapeutic misconception risk in biomedical research? AMA J Ethics 2018; 20: 1100-6.
Lysdahl KB, Hofmann B. Complex health care interventions: characteristics relevant for ethical analysis in health technology assessment. GMS Health Technol Assess 2016; 12: Doc01.
Jiu L, Hogervorst MA, Vreman RA, Mantel-Teeuwisse AK, Goettsch WG. Understanding innovation of health technology assessment methods: the IHTAM framework. Int J Technol Assess Health Care 2022; 38: e16.
Kalf RRJ, Vreman RA, Delnoij DMJ, Bouvy ML, Goettsch WG. Bridging the gap: can International Consortium of Health Outcomes Measurement standard sets align outcomes accepted for regulatory and health technology assessment decision-making of oncology medicines. Pharmacol Res Perspect 2021; 9: e00742.
Sobrero AF, Pastorino A, Zalcberg JR. You're cured till you're not: should disease-free survival be used as a regulatory or clinical end point for adjuvant therapy of cancer? J Clin Oncol 2022; 40: 4044-7.
Carr DR, Bradshaw SE. Gene therapies: the challenge of super-high-cost treatments and how to pay for them. Regen Med 2016; 11: 381-93.
Latimer NR, Towse A, Henshall C. Not cost-effective at zero price: valuing and paying for combination therapies in cancer. Expert Rev Pharmacoecon Outcomes Res 2021; 21: 331-3.
Dankó D, Blay J-Y, Garrison LP. Challenges in the value assessment, pricing and funding of targeted combination therapies in oncology. Health Policy 2019; 123: 1230-6.
Moneer O, Brown BL, Avorn J, Darrow JJ, Mitra-Majumdar M, Joyce KW et al. New drug postmarketing requirements and commitments in the US: a systematic review of the evidence. Drug Saf 2022; 45: 305-18.
Shiragasawa C, Narukawa M. Key characteristics of database studies on drug effectiveness in the postmarketing stage: a systematic review. Pharm Med 2021; 35: 327-38.
Skydel JJ, Zhang AD, Dhruva SS, Ross JS, Wallach JD. US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018. Clin Trials 2021; 18: 488-99.
Stürmer T, Wang T, Golightly YM, Keil A, Lund JL, Jonsson Funk M. Methodological considerations when analysing and interpreting real-world data. Rheumatology 2020; 59: 14-25.
Pace J, Laba T-L, Nisingizwe M-P, Lipworth W. Formulating an ethics of pharmaceutical disinvestment. J Bioeth Inq 2020; 17: 75-86.
Ghinea N. Do doctors have a responsibility to help patients import medicines from abroad? J Med Ethics 2022; 49: 131-5.
Pace J, Ghinea N, Pearson S-A, Kerridge I, Lipworth W. Consumer perspectives of accelerated access to medicines: a qualitative study. J Health Organ Manag 2021; 35: 987-1007.
Cohen AJ, Brody H, Patino G, Ndoye M, Liaw A, Butler C et al. Use of an online crowdfunding platform for unmet financial obligations in cancer care. JAMA Intern Med 2019; 179: 1717-20.
McCabe MS, Faithfull S, Makin W et al. Survivorship programs and care planning. Cancer 2013; 119: 2179-86.